SNY - Nurix Therapeutics: A Unique Approach To BTK Targeting

2024-01-22 08:50:51 ET

Summary

• Positive preliminary results were achieved in early-stage studies of its protein degraders, NX-2127 and NX-5948, for the treatment of B-cell malignancies.
• Protein degradation platform offers several advantages over other BTK drugs, such as ability to overcome mutation resistance and complete removal of BTK scaffolding.
• The global Bruton Tyrosine Kinase [BTK] inhibitors market is expected to reach $27.33 billion by 2031.
• It has been able to generate several partnerships over the years with its protein degrader platform, such as with Gilead Sciences, Pfizer and Sanofi.

Nurix Therapeutics ( NRIX ) has been able to post initial positive results from both of its early-stage studies using its protein degraders known as NX-2127 and NX-5948 for the treatment of patients with B-cell malignancies. Both candidates were able to achieve their intended mechanism of actions that were evaluated. With respect to NX-2127 in the phase 1a/1b study, it was noted that it was able to achieve sustained protein degradation of BTK along with Ikaros degradation as well [targeting of neosubstrates]. On the other hand, with respect to NX-5948 it was shown in a phase 1a/1b study that there was also sustained protein degradation observed. While these trial data are early in nature, I believe that there is a huge opportunity here based on the company's protein degradation platform. Why is that? That's because you have the many available and development-stage Bruton Tyrosine Kinase [BTK] inhibitors that are tackling the large multibillion dollar market....

For further details see: